Highlights

  • Racura Oncology (ASX: RAC) has had its CPACS abstract accepted for a poster presentation at the Global Cardio-Oncology Summit 2026, framing RC220 within the field of cardio-oncology.
  • CPACS is an early-stage, two-part Phase 1 trial pairing RC220 with the anthracycline doxorubicin in adults with advanced solid tumours.
  • The first cohort of three patients showed an acceptable safety profile with no dose-limiting toxicities, allowing the independent Safety Review Committee to permit dose escalation.
  • Cardioprotection remains an exploratory objective and an unproven hypothesis; RC220 is not proven to prevent heart damage or improve survival.
  • Investors should weigh clinical, regulatory, funding, execution and commercialisation risks inherent to any Phase 1 biotechnology program.

Cancer treatment can save lives, yet some of the most effective chemotherapies carry a hidden cost to the heart. This tension sits at the centre of a clinical question now explored by Racura Oncology Limited (ASX: RAC), a Sydney-based Phase 3 clinical-stage biopharmaceutical company. Through a trial called CPACS, Racura is investigating whether its agent RC220 might one day help shield the heart during cancer treatment. The headline poses a genuine question, and it remains open. For Racura Oncology and ASX: RAC, the recent acceptance of a conference abstract marks a milestone in visibility rather than a demonstration of efficacy.

Inside the Announcement

According to Racura's announcement, the company's abstract titled "Cardioprotection and Anticancer Synergy (CPACS) - A Phase 1 Study of RC220 in Combination with Doxorubicin - Trial in Progress" was accepted for a poster presentation at the Global Cardio-Oncology Summit 2026, to be held from 5 to 7 October 2026 in Williamsburg, Virginia. As described in the accepted abstract, CPACS is a multicentre, open-label, two-part Phase 1 trial in adults with advanced solid tumours, with enrolment ongoing in Australia and Hong Kong and participation in South Korea expected to commence.

The company reports that the first cohort of three patients, treated with RC220 at 40 mg/m2 and doxorubicin at 60 mg/m2 over up to five cycles, was reviewed by the independent Safety Review Committee. According to the abstract, the combination was found to have an acceptable safety profile with no dose-limiting toxicity or other significant safety concerns, and the committee allowed escalation to the next RC220 dose level of 80 mg/m2. The abstract concludes that initial safety findings support continued dose escalation, with enrolment ongoing. CEO and Managing Director Dr Daniel Tillett indicated that the acceptance highlights growing interest in RC220's potential to address cardiotoxicity, a key limitation of anthracycline-based therapy. These are early observations attributed to the company and its accepted abstract, and they describe safety, not established efficacy.

Background: Racura Oncology and RC220

Racura Oncology Limited trades on the ASX under the code RAC and describes itself as a Phase 3 clinical-stage biopharmaceutical company with a mission to "silence cancer", led by CEO and Managing Director Dr Daniel Tillett and Executive Chair Dr Peter Smith. The company's lead asset is (E,E)-bisantrene, a small molecule anticancer agent. According to the company, (E,E)-bisantrene primarily acts by binding G-quadruplex (G4) structures in DNA and RNA to silence MYC, also known as c-MYC, an important regulator of cancer growth. The company states that (E,E)-bisantrene has demonstrated therapeutic activity in cancer patients and has a well-characterised safety profile.

RC220 is a proprietary formulation of (E,E)-bisantrene developed by Racura. It sits at the heart of three clinical programs: a Phase 3 program in acute myeloid leukaemia targeting c-MYC silencing; HARNESS-1, a Phase 1 trial combining RC220 with Tagrisso (osimertinib) in mutant EGFR non-small cell lung cancer; and CPACS, the Phase 1 program combining RC220 with doxorubicin in solid tumours. CPACS is distinctive because it aims to explore both enhanced anticancer activity and cardioprotection. Racura has also noted that recent composition-of-matter intellectual property filings may provide up to 20 years of patent protection over (E,E)-bisantrene, and that it is exploring partnerships and licensing opportunities, though nothing has been signed.

Why the Heart Is at Risk: The Cardioprotection Question

Anthracyclines, of which doxorubicin is the best-known example, remain central to many anticancer regimens, used across many tumour types because they are effective at killing cancer cells. Yet their clinical use is limited by a well-recognised drawback: irreversible cardiotoxicity. In plain language, the same treatment that attacks a tumour can also damage the heart muscle, and once that damage occurs it may not heal.

What cardiotoxicity means for patients

For clinicians, this creates a difficult balancing act: the anticancer benefit of an anthracycline must be weighed against cumulative heart risk, sometimes capping the total dose a patient can receive over a lifetime. Heart injury can reduce the heart's pumping ability and, in serious cases, cause lasting cardiac dysfunction long after treatment ends. This is the clinical need that cardio-oncology, the discipline joining cancer care and cardiology, seeks to address.

What "cardioprotection" is designed to explore

Cardioprotection refers to strategies that reduce or prevent this treatment-related heart injury, ideally without blunting the anticancer effect. CPACS is designed to explore whether RC220, given alongside doxorubicin, could contribute to that goal. The cardioprotection objective is exploratory: designing a trial to test a hypothesis is not the same as proving it. Part 1 is a Bayesian Optimal Interval, or BOIN, guided dose-escalation of intravenous RC220 combined with 60 mg/m2 doxorubicin, preceded by monotherapy safety lead-in cycles of each agent. Its primary objective is safety and tolerability, with secondary objectives including the maximum tolerated combined dose, pharmacokinetics, anti-tumour efficacy, and exploratory cardioprotection biomarkers.

Part 2, which follows an interim review, is a dose-expansion cohort to further assess safety, tolerability, preliminary anticancer activity, and protection of cardiac function after anthracycline exposure. The cardiac measures planned for Part 2 include global longitudinal strain (GLS), cardiac magnetic resonance imaging (cMRI), left ventricular ejection fraction (LVEF), cancer therapy-related cardiac dysfunction (CTRCD), cardiac biomarkers, and VO2 peak. These are established tools for detecting changes in heart function; their inclusion signals cardioprotection is being studied seriously, but they are measurements still to be collected, not results already obtained.

Racura has pointed to supportive preclinical work. According to the company, 40 mg/m2 RC220 was protective against doxorubicin-induced cardiotoxicity, and the combination reduced anthracycline cardiotoxicity in human cardiomyocytes and multiple animal cardiac models, while also suggesting improved anticancer activity in human and murine tumour models. These findings are strictly preclinical. They were generated in cells and animals, not in CPACS patients, and do not establish that RC220 will protect the human heart.

What It Could Mean for ASX: RAC

For Racura Oncology and ASX: RAC, the acceptance of the CPACS abstract carries symbolic and scientific value. The poster places RC220 in front of clinicians and researchers at an international summit, reflecting growing interest in its potential to address a known limitation of anthracycline therapy.

That said, investors should keep the milestone in proportion. Abstract acceptance is a visibility event; it is not a clinical result, a regulatory approval, or a partnership. The data so far relate to initial safety in a small first cohort, meaningful for advancing the trial but silent on whether RC220 works as either an anticancer or cardioprotective agent. CPACS is also one of three RC220 programs, so its progress forms part of a broader pipeline narrative, and the path from an accepted abstract to a marketable, proven benefit remains long and uncertain.

Limitations and Key Risks

Several important limitations must temper any enthusiasm. First, CPACS is an early-stage Phase 1 trial, and an acceptable initial safety profile does not establish clinical efficacy. Safety and efficacy are different questions, and giving a combination without dose-limiting toxicity in three patients says nothing definitive about whether it treats cancer or protects the heart. To be explicit: RC220 is not proven to prevent heart damage, and it is not proven to improve survival. The cardioprotection hypothesis remains unproven and under investigation.

Second, preclinical findings are not clinical proof. Encouraging results in cells and animal models often fail to translate into human benefit, and history is full of laboratory signals that did not hold up in patients. Third, regulatory risks apply: early-phase trials must clear multiple review points, and no regulator has approved RC220 for any use. Fourth, funding and execution risks apply: clinical-stage companies typically require ongoing capital, and multicentre trials carry recruitment, operational and timing risks, with enrolment in jurisdictions such as South Korea expected but not yet under way. Finally, commercialisation risk is significant. Even successful trials must be followed by larger studies, regulatory clearance, manufacturing and market access before any product reaches patients, and Racura's exploration of partnerships and licence agreements remains just that, with nothing signed.

What Investors May Watch Next

Grounded in what Racura has disclosed, several signposts may warrant attention. The October 2026 Global Cardio-Oncology Summit poster will share the CPACS trial-in-progress design and initial observations. Continued dose escalation in Part 1, following the Safety Review Committee's clearance to move to 80 mg/m2 RC220, is a natural next step, as is any commencement of enrolment in South Korea. Progress toward the interim review that leads into Part 2, where the exploratory cardioprotection biomarkers such as GLS, cMRI and LVEF are measured, would be a further point of interest, as would updates on the company's other RC220 programs in AML and NSCLC. None of these events guarantees a positive outcome; they are simply the milestones through which the open question may, over time, be explored.

Conclusion

So, could RC220 help protect the heart during cancer treatment? Based on what Racura Oncology (ASX: RAC) has disclosed, the honest answer is that we do not yet know. CPACS has been designed to explore that question, combining RC220 with doxorubicin and building in a suite of cardiac measures to study whether the heart can be protected during anthracycline therapy. But designing a study to test a hypothesis is not the same as confirming it, preclinical protection is not clinical protection, and a clean early safety read is not proof of benefit. For Racura Oncology and ASX: RAC, the coming clinical update is a genuine milestone, yet the question in the headline remains, appropriately, unanswered.